Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2023-01-20 Notice of Dividend Amou…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
EQS-News: BB BIOTECH AG: Uneinheitliche Entwicklung der Biotechaktien spiegeln 2022 die Präferenz von Value gegenüber Wachstum wider – Dividendenvorschlag von CHF 2.85 je Aktie
Notice of Dividend Amount Classification · 99% confidence The document is a press release from BB BIOTECH AG, dated January 20, 2023, summarizing performance for the period ending December 31, 2022. It contains key financial highlights, portfolio performance metrics, management commentary, and a dividend proposal. This structure strongly indicates an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the full year (implied by the headline 'Jahresergebnis' and the date being early in the following year, although it discusses Q4 performance), it functions as the primary announcement of annual results. However, the text explicitly states: "Der vollständige Jahresbericht per 31. Dezember 2022 wird am 17. Februar 2023 veröffentlicht." This means the current document is the preliminary announcement of results, not the comprehensive Annual Report (10-K) or the full Audit Report (AR). Therefore, it fits best as an Earnings Release (ER), which provides the initial announcement of periodical financial results and key highlights. Key indicators supporting ER: 1. Headline mentions 'Jahresergebnis' (Annual Result). 2. Provides net loss figures for the year and Q4. 3. Discusses dividend proposal. 4. Explicitly states the full Annual Report will follow later (ruling out 10-K/AR).
2023-01-20 German
EQS-Adhoc: BB Biotech AG registra una perdita al termine dell’esercizio 2022
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' dated January 20, 2023, reporting the preliminary loss for the full year 2022 (esercizio 2022). It explicitly states that the full Annual Report ('Rapporto annuale completo') will be published later on February 17, 2023. Since this document is a short, preliminary announcement of financial results (loss of CHF 358 million) and directs the reader to a future, more comprehensive report, it fits the definition of an Earnings Release (ER) which covers initial announcements of periodical financial results (key highlights only). It is not the full 10-K, nor is it a comprehensive Interim Report (IR) as it covers the full year, albeit preliminarily. The structure (Ad hoc announcement pursuant to Art. 53 LR) strongly suggests a mandatory, timely disclosure of key figures, aligning best with ER. FY 2022
2023-01-20 Italian
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' dated January 20, 2023, disclosing preliminary, unaudited consolidated figures for the 2022 fiscal year, specifically reporting a loss. It explicitly states that the 'complete annual report will be published on February 17, 2023.' Since this document only provides the initial, high-level results announcement for the period (a loss figure) and points to a future, complete report, it fits the definition of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but the initial release of period results. FY 2022
2023-01-20 English
EQS-Adhoc: BB Biotech AG mit Verlust im Geschäftsjahr 2022
Earnings Release Classification · 100% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) dated January 20, 2023, reporting the preliminary loss for the 'Geschäftsjahr 2022' (Fiscal Year 2022). It explicitly states the preliminary results (CHF 358 million loss) and mentions that the full annual report ('vollständige Geschäftsbericht') will be published later (February 17, 2023). Since this is the initial, brief announcement of the period's financial results, it fits the definition of an Earnings Release (ER). The document length is short (2794 chars), and it serves as the initial release of key financial highlights for the period, not the comprehensive report itself. FY 2022
2023-01-20 German
BB BIOTECH AG: Molecular strike force for the immune system
Regulatory Filings Classification · 95% confidence The document is a market commentary and investment update published by BB Biotech AG. It discusses specific portfolio companies (Argenx, Celldex, Kezar), investment strategies, and market trends in the biotech sector. It does not constitute a formal financial report (like a 10-K or IR), nor is it a simple announcement of a report release. It functions as corporate news/investor communication regarding market outlook and portfolio performance, which falls under the 'Regulatory Filings' (RNS) category as a general corporate news dissemination. Q3 2022
2022-12-08 English
EQS-News: BB BIOTECH AG: Forza d’intervento rapido molecolare per il sistema immunitario
Management Reports Classification · 99% confidence The document is titled 'EQS-News: BB BIOTECH AG / Parola (s): Bollettino di mercato' and is dated 08.12.2022. It contains commentary from an investment manager ('Dr. Daniel Koller, responsabile Team di gestione degli investimenti di BB Biotech') discussing investment opportunities in autoimmune disease therapies, specifically mentioning portfolio companies like Argenx, Celldex Therapeutics, and Kezar Life Sciences, and providing financial context (e.g., Argenx's Q3 revenue). This structure—a market commentary or analysis piece released via a news service (EQS-News) that discusses investment strategy and portfolio performance—is characteristic of an Investor Presentation (IP) or a detailed market commentary that functions similarly to an investor update, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses strictly on period results. Given the depth of strategic discussion and portfolio review, 'Investor Presentation' (IP) is the most fitting category, as it often includes management commentary on market trends and specific holdings, even if presented as a 'Bollettino di mercato' (Market Bulletin). It is not a short announcement of a report (RPA/RNS), but the content itself.
2022-12-08 Italian

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.